Loading...
Header Logo
Keywords
Last Name
Institution

Wen Xue PhD

TitleAssistant Professor
InstitutionUniversity of Massachusetts Medical School
DepartmentRNA Therapeutics Institute
AddressUniversity of Massachusetts Medical School
368 Plantation Street, Shermann Center
Worcester MA 01605
vCardDownload vCard
    Other Positions
    InstitutionUMMS - School of Medicine
    DepartmentProgram in Molecular Medicine

    InstitutionUMMS - School of Medicine
    DepartmentRNA Therapeutics Institute

    InstitutionUMMS - Graduate School of Biomedical Sciences
    DepartmentBiochemistry and Molecular Pharmacology

    InstitutionUMMS - Graduate School of Biomedical Sciences
    DepartmentCancer Biology

    InstitutionUMMS - Graduate School of Biomedical Sciences
    DepartmentInterdisciplinary Graduate Program


    Collapse ORNG Applications 
    Collapse Twitter
    Collapse Websites

    Collapse Biography 
    Collapse education and training
    Nanjing University, Nanjing, , ChinaBSBiochemistry
    Nanjing University, Nanjing, , ChinaMSBiochemistry
    State University of New York, Stony Brook, Stony Brook, NY, United StatesPHDBiochemistry
    Collapse awards and honors
    2014 - 2017Pathway to independence award 4R00CA169512-03, NIH
    2015 - 2016Scientific Merit Award, the Lung Cancer Research Foundation
    2015 - 2016Worcester Foundation Grant, Worcester Foundation
    2015 - 2016President’s Science and Technology (S&T) Fund , UMass
    2016 - 2020Research Scholars Grant , American Cancer Society
    2015Session co-chair, International Liver Cancer Association (ILCA) annual meeting
    2016 - 2021P01HL131471, NHLBI/NIH
    2016 - 2021NIH Director’s New Innovator Award, NIH
    2016 - 2018Research fund, the Lung Cancer Research Foundation
    2016 - 2018Pediatric Cancer Grant , Hyundai Hope On Wheels

    Collapse Overview 
    Collapse overview

    My lab will develop genetic models of liver and lung cancer using small RNA tools, such as RNAi-mediated silencing and CRISPR/Cas9-mediated genome editing. The CRISPR/Cas9 system allows us to quickly generate somatic loss-of-function mutations in tumor suppressor genes or gain-of-function mutations in oncogenes. Our approach presents a new avenue for rapid development of cancer models, functional genomics, and proof-of-concept targeted cancer therapy. My laboratory will engage in the following areas of research over the next few years:


    Discover and correct liver cancer genes using CRISPR-mediated genome editing


    Many candidate cancer genes are being discovered through cancer genome-sequencing efforts, and simple genetic methods are needed to validate candidate cancer genes in vivo. CRISPR/Cas genome-editing has been successfully used in many organisms, including mouse and human cells. We will use in vivo CRISPR/Cas-mediated genome editing tools to discover, validate, and correct liver cancer genes in the mouse. To identify potential liver cancer therapeutic targets, we will devise novel CRISPR strategies to delete candidate oncogenes and test the effect on liver cancer progression. Because our approach allows us to perform genetic tests without breeding mice, our approach will speed up cancer gene discovery and drug target validation for liver cancer.


    Characterize response and resistance to KRAS inhibition using in vivo RNAi and genome editing


    KRAS is mutated in >30% of lung cancer. While most studies in the literature use inducible Kras cDNA, conditional shRNA system allows knockdown of endogenous levels of Kras in vivo, offering a more physiologic model of Kras inhibition. We will model the response and resistance to Kras inhibition in mouse models using lentiviral-based tet-on shRNA in the lung. Our recent studies show that after long-term Kras inhibition by RNAi, Kras-driven tumors relapse and become Kras-independent. We will explore the molecular basis of resistance to Kras inhibition using gene expression profiling. To completely delete the oncogenic KRAS gene and compare the phenotype with RNAi-mediated knockdown, we plan to use CRISPR to generate floxed KRAS conditional knockout alleles in lung cancer cell lines. These small RNA-based experiments will generate in vivo and in vitro platforms to uncover important KRAS biology.


    Investigate oncogenic and tumor suppressor miRNA networks in lung cancer


    MicroRNAs (miRNAs) are small, non-coding RNAs that regulate mRNA translation or stability. Delineating miRNA networks can identify new miRNAs and miRNA antagonists for lung cancer treatment. We will cross-compare human lung adenocarcinoma miRNA expression profiles and cancer genome copy number analyses from TCGA (the Cancer Genome Atlas) to identify candidate miRNAs that drive or suppress tumor formation. We will use tet-on miRNA expression system to conditionally express miRNA at various stages of tumor progression and study the impact on tumor growth in vivo. Together, these studies will unveil miRNA networks in cancer using genetic tools.  



    Collapse Rotation Projects


    Our lab uses CRISPR tools to speed up cancer gene discovery and disease gene repair. Rotation projects are available to explore experimental techniques such as molecular cloning of CRISPR plasmids, measuring genome-editing efficiency, dissecting mice, and processing of mouse tumor/tissue for histology.



    Collapse Post Docs


    We are looking for postdoc candidates with experience in cancer biology, mouse models and genome-engineering. Please email CV and 3 letters of recommendation to Wen.Xue@umassmed.edu.




    Collapse Research 
    Collapse research activities and funding
    129056-RSG-16-093     (Wen Xue)Jul 1, 2016 - Jun 30, 2020
    ACS
    An integrative approach to study KRAS inhibition in lung cancer

    P01HL131471     (Terry Flotte)Aug 5, 2016 - Apr 30, 2021
    NIH
    New Approaches to Gene Therapy for Alpha-1 Antitrypsin Deficiency
    Role: co-I / leader of Project 3

    DP2HL137167     (XUE, WEN)Sep 30, 2016 - Jun 30, 2021
    NIH
    CRISPR-based modular therapy for precision medicine
    Role: Principal Investigator

    UG3HL147367     (Guangping Gao/Wen Xue/Dan Anderson)Sep 10, 2018 - Jul 30, 2021
    NIH
    Develop combinatorial non-viral and viral CRISPR delivery for lung diseases
    Role: co-PI

         (Wen Xue/Guangping Gao)Jul 1, 2019 - Jun 30, 2022
    Cystic fibrosis foundation
    Template-free repair of CFTR mutations by base editing and allelic exchange
    Role Description: To develop new base editing and allelic exchange tools for CFTR mutations.
    Role: PI

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Lee J, Mou H, Ibraheim R, Liang SQ, Liu P, Xue W, Sontheimer EJ. Tissue-restricted Genome Editing in vivo Specified by MicroRNA-repressible Anti-CRISPR Proteins. RNA. 2019 Aug 22. PMID: 31439808.
      View in: PubMed
    2. Elaimy AL, Sheel A, Brown CW, Walker MR, Wang M, Amante JJ, Xue W, Chan A, Baer CE, Goel HL, Mercurio AM. Real-time imaging of integrin ß4 dynamics using a reporter cell line generated by Crispr/Cas9 genome editing. J Cell Sci. 2019 Jul 01. PMID: 31262785.
      View in: PubMed
    3. Kwan SY, Sheel A, Song CQ, Zhang XO, Jiang T, Dang H, Cao Y, Ozata DM, Mou H, Yin H, Weng Z, Wang XW, Xue W. Depletion of TRRAP induces p53-independent senescence in liver cancer by downregulating mitotic genes. Hepatology. 2019 Jun 12. PMID: 31188495.
      View in: PubMed
    4. Mou H, Ozata DM, Smith JL, Sheel A, Kwan SY, Hough S, Kucukural A, Kennedy Z, Cao Y, Xue W. CRISPR-SONIC: targeted somatic oncogene knock-in enables rapid in vivo cancer modeling. Genome Med. 2019 Apr 16; 11(1):21. PMID: 30987660.
      View in: PubMed
    5. Wang W, Yang J, Edin ML, Wang Y, Luo Y, Wan D, Yang H, Song CQ, Xue W, Sanidad KZ, Song M, Bisbee HA, Bradbury JA, Nan G, Zhang J, Shih PB, Lee KSS, Minter LM, Kim D, Xiao H, Liu JY, Hammock BD, Zeldin DC, Zhang G. Targeted metabolomics identifies the cytochrome P450 monooxygenase eicosanoid pathway as a novel therapeutic target of colon tumorigenesis. Cancer Res. 2019 Feb 25. PMID: 30803995.
      View in: PubMed
    6. Song CQ, Jiang T, Richter M, Rhym LH, Koblan LW, Zafra MP, Schatoff EM, Doman JL, Cao Y, Dow LE, Zhu LJ, Anderson DG, Liu DR, Yin H, Xue W. Adenine base editing in an adult mouse model of tyrosinaemia. Nat Biomed Eng. 2019 Feb 25. PMID: 31740768.
      View in: PubMed
    7. Moon SH, Huang CH, Houlihan SL, Regunath K, Freed-Pastor WA, Morris JP, Tschaharganeh DF, Kastenhuber ER, Barsotti AM, Culp-Hill R, Xue W, Ho YJ, Baslan T, Li X, Mayle A, de Stanchina E, Zender L, Tong DR, D'Alessandro A, Lowe SW, Prives C. p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression. Cell. 2019 Jan 24; 176(3):564-580.e19. PMID: 30580964.
      View in: PubMed
    8. Edraki A, Mir A, Ibraheim R, Gainetdinov I, Yoon Y, Song CQ, Cao Y, Gallant J, Xue W, Rivera-Pérez JA, Sontheimer EJ. A Compact, High-Accuracy Cas9 with a Dinucleotide PAM for In Vivo Genome Editing. Mol Cell. 2018 Dec 18. PMID: 30581144.
      View in: PubMed
    9. Smith JL, Mou H, Xue W. Understanding and repurposing CRISPR-mediated alternative splicing. Genome Biol. 2018 Nov 06; 19(1):184. PMID: 30400804.
      View in: PubMed
    10. Ibraheim R, Song CQ, Mir A, Amrani N, Xue W, Sontheimer EJ. All-in-one adeno-associated virus delivery and genome editing by Neisseria meningitidis Cas9 in vivo. Genome Biol. 2018 Sep 19; 19(1):137. PMID: 30231914.
      View in: PubMed
    11. Zhang XO, Fu Y, Mou H, Xue W, Weng Z. The temporal landscape of recursive splicing during Pol II transcription elongation in human cells. PLoS Genet. 2018 Aug; 14(8):e1007579. PMID: 30148885.
      View in: PubMed
    12. Wang D, Li J, Song CQ, Tran K, Mou H, Wu PH, Tai PWL, Mendonca CA, Ren L, Wang BY, Su Q, Gessler DJ, Zamore PD, Xue W, Gao G. Cas9-mediated allelic exchange repairs compound heterozygous recessive mutations in mice. Nat Biotechnol. 2018 Aug 13. PMID: 30102296.
      View in: PubMed
    13. Song CQ, Wang D, Jiang T, O'Connor K, Tang Q, Cai L, Li X, Weng Z, Yin H, Gao G, Mueller C, Flotte TR, Xue W. In vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency. Hum Gene Ther. 2018 May 14. PMID: 29597895.
      View in: PubMed
    14. Song CQ, Xue W. CRISPR-Cas-related technologies in basic and translational liver research. Nat Rev Gastroenterol Hepatol. 2018 Feb 14. PMID: 29443117.
      View in: PubMed
    15. Yin H, Song CQ, Suresh S, Kwan SY, Wu Q, Walsh S, Ding J, Bogorad RL, Zhu LJ, Wolfe SA, Koteliansky V, Xue W, Langer R, Anderson DG. Partial DNA-guided Cas9 enables genome editing with reduced off-target activity. Nat Chem Biol. 2018 Mar; 14(3):311-316. PMID: 29377001.
      View in: PubMed
    16. Yin H, Song CQ, Suresh S, Wu Q, Walsh S, Rhym LH, Mintzer E, Bolukbasi MF, Zhu LJ, Kauffman K, Mou H, Oberholzer A, Ding J, Kwan SY, Bogorad RL, Zatsepin T, Koteliansky V, Wolfe SA, Xue W, Langer R, Anderson DG. Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nat Biotechnol. 2017 Nov 13. PMID: 29131148.
      View in: PubMed
    17. Dang H, Takai A, Forgues M, Pomyen Y, Mou H, Xue W, Ray D, Ha KCH, Morris QD, Hughes TR, Wang XW. Oncogenic Activation of the RNA Binding Protein NELFE and MYC Signaling in Hepatocellular Carcinoma. Cancer Cell. 2017 Jul 10; 32(1):101-114.e8. PMID: 28697339.
      View in: PubMed
    18. Mou H, Smith JL, Peng L, Yin H, Moore J, Zhang XO, Song CQ, Sheel A, Wu Q, Ozata DM, Li Y, Anderson DG, Emerson CP, Sontheimer EJ, Moore MJ, Weng Z, Xue W. CRISPR/Cas9-mediated genome editing induces exon skipping by alternative splicing or exon deletion. Genome Biol. 2017 Jun 14; 18(1):108. PMID: 28615073.
      View in: PubMed
    19. Tammela T, Sanchez-Rivera FJ, Cetinbas NM, Wu K, Joshi NS, Helenius K, Park Y, Azimi R, Kerper NR, Wesselhoeft RA, Gu X, Schmidt L, Cornwall-Brady M, Yilmaz ÖH, Xue W, Katajisto P, Bhutkar A, Jacks T. A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. Nature. 2017 05 18; 545(7654):355-359. PMID: 28489818.
      View in: PubMed
    20. Mou H, Moore J, Malonia SK, Li Y, Ozata DM, Hough S, Song CQ, Smith JL, Fischer A, Weng Z, Green MR, Xue W. Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis. Proc Natl Acad Sci U S A. 2017 Mar 20. PMID: 28320962.
      View in: PubMed
    21. Xue WL, Cai WJ, Tao BB, Wang MJ, Li XH, Zhu YC. [The Molecular Switches and Atomic Biological Mechanisms Underlying the Physiological and Pathophysio-logical Effects of Hydrogen Sulfide to Regulate Its "Receptors"]. Sheng Li Ke Xue Jin Zhan. 2017 Feb; 48(1):12-21. PMID: 29927215.
      View in: PubMed
    22. Song CQ, Li Y, Mou H, Moore J, Park A, Pomyen Y, Hough S, Kennedy Z, Fischer A, Yin H, Anderson DG, Conte D, Zender L, Wang XW, Thorgeirsson S, Weng Z, Xue W. Genome-wide CRISPR Screen Identifies Regulators of MAPK as Suppressors of Liver Tumors in Mice. Gastroenterology. 2016 Dec 09. PMID: 27956228.
      View in: PubMed
    23. Sheel A, Xue W. Genomic Amplifications Cause False Positives in CRISPR Screens. Cancer Discov. 2016 Aug; 6(8):824-6. PMID: 27485003.
      View in: PubMed
    24. Akama-Garren EH, Joshi NS, Tammela T, Chang GP, Wagner BL, Lee DY, Rideout WM, Papagiannakopoulos T, Xue W, Jacks T. A Modular Assembly Platform for Rapid Generation of DNA Constructs. Sci Rep. 2016 Feb 18; 6:16836. PMID: 26887506.
      View in: PubMed
    25. Yin H, Song CQ, Dorkin JR, Zhu LJ, Li Y, Wu Q, Park A, Yang J, Suresh S, Bizhanova A, Gupta A, Bolukbasi MF, Walsh S, Bogorad RL, Gao G, Weng Z, Dong Y, Koteliansky V, Wolfe SA, Langer R, Xue W, Anderson DG. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol. 2016 Mar; 34(3):328-33. PMID: 26829318.
      View in: PubMed
    26. Yin H, Bogorad RL, Barnes C, Walsh S, Zhuang I, Nonaka H, Ruda V, Kuchimanchi S, Nechev L, Akinc A, Xue W, Zerial M, Langer R, Anderson DG, Koteliansky V. RNAi-nanoparticulate manipulation of gene expression as a new functional genomics tool in the liver. J Hepatol. 2016 Apr; 64(4):899-907. PMID: 26658687.
      View in: PubMed
    27. Xue W, Wang XW. The search for precision models clinically relevant to human liver cancer. Hepat Oncol. 2015 Oct; 2(4):315-319. PMID: 30191010.
      View in: PubMed
    28. Wang D, Mou H, Li S, Li Y, Hough S, Tran K, Li J, Yin H, Anderson DG, Sontheimer EJ, Weng Z, Gao G, Xue W. Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses. Hum Gene Ther. 2015 Jul; 26(7):432-42. PMID: 26086867.
      View in: PubMed
    29. Mou H, Kennedy Z, Anderson DG, Yin H, Xue W. Precision cancer mouse models through genome editing with CRISPR-Cas9. Genome Med. 2015; 7(1):53. PMID: 26060510.
      View in: PubMed
    30. Li Y, Park AI, Mou H, Colpan C, Bizhanova A, Akama-Garren E, Joshi N, Hendrickson EA, Feldser D, Yin H, Anderson DG, Jacks T, Weng Z, Xue W. A versatile reporter system for CRISPR-mediated chromosomal rearrangements. Genome Biol. 2015 May 28; 16:111. PMID: 26018130.
      View in: PubMed
    31. Khan OF, Zaia EW, Jhunjhunwala S, Xue W, Cai W, Yun DS, Barnes CM, Dahlman JE, Dong Y, Pelet JM, Webber MJ, Tsosie JK, Jacks TE, Langer R, Anderson DG. Dendrimer-Inspired Nanomaterials for the in Vivo Delivery of siRNA to Lung Vasculature. Nano Lett. 2015 May 13; 15(5):3008-16. PMID: 25789998.
      View in: PubMed
    32. Li J, Chanrion M, Sawey E, Wang T, Chow E, Tward A, Su Y, Xue W, Lucito R, Zender L, Lowe SW, Bishop JM, Powers S. Reciprocal interaction of Wnt and RXR-a pathways in hepatocyte development and hepatocellular carcinoma. PLoS One. 2015; 10(3):e0118480. PMID: 25738607.
      View in: PubMed
    33. Sánchez-Rivera FJ, Papagiannakopoulos T, Romero R, Tammela T, Bauer MR, Bhutkar A, Joshi NS, Subbaraj L, Bronson RT, Xue W, Jacks T. Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature. 2014 Dec 18; 516(7531):428-31. PMID: 25337879.
      View in: PubMed
    34. Xue W, Dahlman JE, Tammela T, Khan OF, Sood S, Dave A, Cai W, Chirino LM, Yang GR, Bronson R, Crowley DG, Sahay G, Schroeder A, Langer R, Anderson DG, Jacks T. Small RNA combination therapy for lung cancer. Proc Natl Acad Sci U S A. 2014 Aug 26; 111(34):E3553-61. PMID: 25114235.
      View in: PubMed
    35. Xue W, Chen S, Yin H, Tammela T, Papagiannakopoulos T, Joshi NS, Cai W, Yang G, Bronson R, Crowley DG, Zhang F, Anderson DG, Sharp PA, Jacks T. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature. 2014 Oct 16; 514(7522):380-4. PMID: 25119044.
      View in: PubMed
    36. Tschaharganeh DF, Xue W, Calvisi DF, Evert M, Michurina TV, Dow LE, Banito A, Katz SF, Kastenhuber ER, Weissmueller S, Huang CH, Lechel A, Andersen JB, Capper D, Zender L, Longerich T, Enikolopov G, Lowe SW. p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. Cell. 2014 Jul 31; 158(3):579-92. PMID: 25083869.
      View in: PubMed
    37. Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X, Schinzel AC, Sood S, Rosenbluh J, Kim JW, Zwang Y, Roberts TM, Root DE, Jacks T, Hahn WC. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 2014 Jul 3; 158(1):171-84. PMID: 24954536.
      View in: PubMed
    38. Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, Grompe M, Koteliansky V, Sharp PA, Jacks T, Anderson DG. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol. 2014 Jun; 32(6):551-3. PMID: 24681508.
      View in: PubMed
    39. Xue W, Kitzing T, Roessler S, Zuber J, Krasnitz A, Schultz N, Revill K, Weissmueller S, Rappaport AR, Simon J, Zhang J, Luo W, Hicks J, Zender L, Wang XW, Powers S, Wigler M, Lowe SW. A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proc Natl Acad Sci U S A. 2012 May 22; 109(21):8212-7. PMID: 22566646.
      View in: PubMed
    40. Oliver TG, Meylan E, Chang GP, Xue W, Burke JR, Humpton TJ, Hubbard D, Bhutkar A, Jacks T. Caspase-2-mediated cleavage of Mdm2 creates a p53-induced positive feedback loop. Mol Cell. 2011 Jul 8; 43(1):57-71. PMID: 21726810.
      View in: PubMed
    41. Xue W, Meylan E, Oliver TG, Feldser DM, Winslow MM, Bronson R, Jacks T. Response and resistance to NF-?B inhibitors in mouse models of lung adenocarcinoma. Cancer Discov. 2011 Aug; 1(3):236-47. PMID: 21874163.
      View in: PubMed
    42. Liu LX, Lee NP, Chan VW, Xue W, Zender L, Zhang C, Mao M, Dai H, Wang XL, Xu MZ, Lee TK, Ng IO, Chen Y, Kung HF, Lowe SW, Poon RT, Wang JH, Luk JM. Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology. 2009 Nov; 50(5):1453-63. PMID: 19676131.
      View in: PubMed
    43. Krizhanovsky V, Xue W, Zender L, Yon M, Hernando E, Lowe SW. Implications of cellular senescence in tissue damage response, tumor suppression, and stem cell biology. Cold Spring Harb Symp Quant Biol. 2008; 73:513-22. PMID: 19150958.
      View in: PubMed
    44. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, Zender P, Kubicka S, Luk JM, Schirmacher P, McCombie WR, Wigler M, Hicks J, Hannon GJ, Powers S, Lowe SW. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell. 2008 Nov 28; 135(5):852-64. PMID: 19012953.
      View in: PubMed
    45. Gyrd-Hansen M, Darding M, Miasari M, Santoro MM, Zender L, Xue W, Tenev T, da Fonseca PC, Zvelebil M, Bujnicki JM, Lowe S, Silke J, Meier P. IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis. Nat Cell Biol. 2008 Nov; 10(11):1309-17. PMID: 18931663.
      View in: PubMed
    46. Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, Hannon GJ, Lowe SW, Hemann MT. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A. 2008 Jul 1; 105(26):9053-8. PMID: 18574145.
      View in: PubMed
    47. Xue W, Krasnitz A, Lucito R, Sordella R, Vanaelst L, Cordon-Cardo C, Singer S, Kuehnel F, Wigler M, Powers S, Zender L, Lowe SW. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev. 2008 Jun 1; 22(11):1439-44. PMID: 18519636.
      View in: PubMed
    48. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW, Cleary MA, Hannon GJ. A microRNA component of the p53 tumour suppressor network. Nature. 2007 Jun 28; 447(7148):1130-4. PMID: 17554337.
      View in: PubMed
    49. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007 Feb 8; 445(7128):656-60. PMID: 17251933.
      View in: PubMed
    50. Lakshmi B, Hall IM, Egan C, Alexander J, Leotta A, Healy J, Zender L, Spector MS, Xue W, Lowe SW, Wigler M, Lucito R. Mouse genomic representational oligonucleotide microarray analysis: detection of copy number variations in normal and tumor specimens. Proc Natl Acad Sci U S A. 2006 Jul 25; 103(30):11234-9. PMID: 16844783.
      View in: PubMed
    51. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, Mu D, Lucito R, Powers S, Lowe SW. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006 Jun 30; 125(7):1253-67. PMID: 16814713.
      View in: PubMed
    52. Zender L, Xue W, Cordón-Cardo C, Hannon GJ, Lucito R, Powers S, Flemming P, Spector MS, Lowe SW. Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors. Cold Spring Harb Symp Quant Biol. 2005; 70:251-61. PMID: 16869761.
      View in: PubMed
    53. Xue W, Wang J, Shen Z, Zhu H. Enrichment of transcriptional regulatory sites in non-coding genomic region. Bioinformatics. 2004 Mar 1; 20(4):569-75. PMID: 14990453.
      View in: PubMed
    For assistance with using Profiles, please refer to the online tutorials or contact UMMS Help Desk or call 508-856-8643.
    Xue's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _